Here's Why Shares in PTC Therapeutics Soared This Week

Key Points

• Management believes that the commercial opportunity, combined with its cash reserves, will enable its cash flow to reach breakeven.

• The drug has been approved in the U.S. and Europe, and PTC Therapeutics is just starting to commercialize it.

• Look out for an update on the third-quarter earnings call.

• 10 stocks we like better than Ptc Therapeutics ›

Shares in PTC Therapeutics (NASDAQ: PTCT) surged by 17.5% in the week to Friday morning, as the market digested management's upbeat presentation at the Cantor Global Healthcare Conference on Wednesday.

What management said at the Cantor Global Healthcare Conference

CEO Matthew Klein's presentation focused on the commercial market opportunity for Sephience, an orally administered therapy for treating phenylketonuria (PKU). Sephience has been approved in the U.S. and Europe, as it lowers the abnormally high levels of amino acid phenylalanine that builds up in PKU sufferers. It's a condition that puts severe dietary restrictions on PKU sufferers.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Klein believes that the majority of patients on the drug will be responders and could achieve significant reductions in phenylalanine. PTC has a $1 billion commercial opportunity in the U.S. and a $500 million commercial opportunity outside the U.S.

Moreover, Klein said the words that every investor in a young growth stock wants to hear, namely that PTC's cash balance and growing sales from Sephience will take the company to cash-flow breakeven before long. That's a key point because it implies PTC might need to raise capital in the future, and can fund its developmental program without issuing debt or selling equity.

Image source: Getty Images.

What's next for PTC Therapeutics

Klein promised an update on Sephience and initial progress on commercializing the drug, including data on patient start forms in the U.S., as well as the number of commercial patients on the drug in the U.S. and internationally -- something to look out for when the company reports, likely in early November.

Should you invest $1,000 in Ptc Therapeutics right now?

Before you buy stock in Ptc Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ptc Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $678,148!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,052,193!*

Now, it’s worth noting Stock Advisor’s total average return is 1,065% — a market-crushing outperformance compared to 186% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of August 25, 2025

Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.